Results
1 -
10 of
98Koga Yuichi, Sakamaki Shigeki, Hongu Mitsuya, Kawanishi Eiji, Sakamoto Toshiaki, Yamamoto Yasuo, Kimata Hirotaka, Nakayama Keiko, Kuriyama Chiaki, Matsushita Yasuaki, Ueta Kiichiro, Tsuda-Tsukimoto Minoru, Nomura Sumihiro.
C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors, Bioorganic & Medicinal Chemistry, 2013 Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect, Cell Death & Disease Development of Efficient Routes to Access C-Glycosides as SGLT-2 Inhibitors for the Treatment of Type 2 Diabetes, Synthesis of Heterocycles in Contemporary Medicinal Chemistry SGLT2 Inhibitors for Treating Diabetes, Essentials of SGLT2 Inhibitors in Diabetes Using SGLT2 Inhibitors in Special Populations, Essentials of SGLT2 Inhibitors in Diabetes Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials, Diabetologia Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation, Diabetologia Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial, Diabetologia Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes, Diabetologia Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes, Diabetologia